The biologics industry has a dirty secret: making these drugs is expensive, unpredictable, and often wasteful. ChemT Biotechnology thinks it has a solution—and investors are betting $4 million that it's right.
The Singapore-based startup announced the seed round on June 22, securing backing from Wavemaker Ventures, SEEDS (part of SG Growth Capital), Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator. The raise brings ChemT's total funding to $5 million since its August 2023 founding—not bad for a company tackling one of biopharma's most unglamorous bottlenecks.
At issue is this: producing biologics, from monoclonal antibodies to cutting-edge cell therapies, remains stubbornly inefficient. Yields are low. Timelines are long. Costs pile up. For an industry racing to deliver personalized cancer treatments and next-generation therapeutics, that's more than an annoyance. It's a constraint.
ChemT's pitch is that artificial intelligence can change the calculus.
Small Molecules, Big Impact
The company's platform, called CelMo, is what founder and CEO Jie Sun describes as an "AI Virtual Cell." Trained on what ChemT characterizes as billions to trillions of proprietary sequencing reads, the system identifies biological pathways and designs small molecules to tweak cell behavior during manufacturing. Those molecules are then tested in actual wet lab conditions—a hybrid approach that tries to marry computational prediction with real-world validation.
The company says its lead product, Chemplify, gets added during cell expansion at roughly 1:10,000 dilution. Applied to CHO cells (the workhorses of antibody production), ChemT claims a 50% bump in antibody output and a 40% cut in production timelines. In T-cell expansion for cell and gene therapies, the numbers get more eye-catching: yield increases up to tenfold, cost reductions of 60%, and development cycles halved.
Those figures, disclosed alongside the funding announcement, haven't been independently verified at scale. But they're grounded in published research. A May 2026 supplement in the Journal of Cytokine Biology detailed the dilution protocol, while abstracts from scientific meetings in March 2025 and May 2026 described five- to tenfold expansion improvements in T-cells while preserving desired cell characteristics—capabilities the researchers noted remain "underexplored" in commercial manufacturing.
Still, laboratory promise and GMP-validated manufacturing are different animals. ChemT will need to prove its technology holds up under the regulatory scrutiny that defines this industry.
Forty Partners in Eighteen Months
For a company barely two years old, ChemT has moved quickly. It claims more than 40 commercial partnerships spanning pharma, biotech, and contract development and manufacturing organizations, though it hasn't publicly named most of them.
One disclosed collaboration is with CARsgen Therapeutics, announced in December 2025, focused on accelerating next-generation cell therapy development. ChemT also lists itself as a member of Eli Lilly's AI/ML-enabled TuneLab, launched in September 2025—though independent confirmation of that membership wasn't readily available in public sources.
The founding team brings complementary expertise. Sun, who holds a master's in health data science from Harvard, previously co-founded Basys.ai. President Ling Wu, PhD, is a cancer immunologist with more than a decade in cell and gene therapy research, including a stint as principal investigator at BeiGene. It's the kind of pairing—computational chops meets wet lab credibility—that investors in this space tend to like.
The Market Math
ChemT's timing may be fortuitous. The broader manufacturing landscape is shifting in ways that could favor its technology.
According to a spring 2026 report in European Biotechnology, roughly 90% of biotech companies now outsource manufacturing to CDMOs. Industry data from Rx Almanac, published between April and May 2026, pegs the global pharma CDMO market somewhere between $230 billion and $275 billion, with biologics fill-finish and cell and gene therapy segments growing fastest.
Cell and gene therapy manufacturing, in particular, remains vexing. Academic reviews published in 2025 in the Journal of Controlled Release and Frontiers in Immunology consistently cite scalability, consistency, and cost as enduring challenges. A February 2026 whitepaper from ElevateBio and Sartorius suggested that closed, digital, automated platforms could potentially increase batch throughput by more than tenfold—a finding that underscores industry hunger for the kind of yield and quality improvements ChemT is promising.
Whether the company can deliver on that promise at commercial scale is the open question. The fresh capital will go toward expanding AI and experimental infrastructure, advancing molecular products toward GMP readiness, and scaling commercial partnerships. In other words: proving the technology works beyond the lab bench.
The Regulatory Gauntlet
ChemT now faces what every biotech eventually confronts—the gap between compelling early data and the reproducible, validated processes regulators demand. In an industry where contamination, batch variability, or even minor deviations can derail approvals or trigger costly recalls, consistency isn't optional.
The company's challenge will be translating its AI-designed molecules into manufacturing protocols that CDMOs and pharma partners can trust. That means demonstrating not just efficacy, but robustness across multiple production runs, facilities, and therapeutic contexts.
If it succeeds, ChemT could tap into a market eager for solutions. If it stumbles, it'll join a long list of biotechs whose lab-stage breakthroughs never quite made the leap to commercial viability.
For now, though, investors seem willing to bet that the company is onto something. And in a field where incremental improvements can unlock billions in value, even a modest edge in manufacturing efficiency could prove transformative.
